Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

S. Peters; U. Dafni; M. Boyer; D. De Ruysscher; C. Faivre-Finn; E. Felip; P. Garrido; N. Girard; M. Guckenberger; J. Haanen; C. Le Pechoux; F. Mornex; M. Ozsahin; L. Paz-Ares; D. Planchard; D. Raben; S. Ramalingam; M. Reck; E. Smit; R. Stahel; A. Stenzinger; C. Swanton; S. Vallone; M. C. Garassino

doi:10.1093/annonc/mdy553

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

S. Peters^*, U. Dafni, M. Boyer, D. De Ruysscher, C. Faivre-Finn, E. Felip, P. Garrido, N. Girard, M. Guckenberger, J. Haanen, C. Le Pechoux, F. Mornex, M. Ozsahin, L. Paz-Ares, D. Planchard, D. Raben, S. Ramalingam, M. Reck, E. Smit, R. StahelA. Stenzinger, C. Swanton, S. Vallone, M. C. Garassino

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	161-165
Number of pages	5
Journal	Annals of Oncology
Volume	30
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mdy553
Publication status	Published - Feb 2019

Keywords

PROGRAMMED DEATH LIGAND-1
CLINICAL BENEFIT
RADIOTHERAPY
EXPRESSION
MAGNITUDE
PD-L1

Access to Document

10.1093/annonc/mdy553

Cite this

Peters, S., Dafni, U., Boyer, M., De Ruysscher, D., Faivre-Finn, C., Felip, E., Garrido, P., Girard, N., Guckenberger, M., Haanen, J., Le Pechoux, C., Mornex, F., Ozsahin, M., Paz-Ares, L., Planchard, D., Raben, D., Ramalingam, S., Reck, M., Smit, E., ... Garassino, M. C. (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 30(2), 161-165. https://doi.org/10.1093/annonc/mdy553

Peters, S. ; Dafni, U. ; Boyer, M. ; De Ruysscher, D. ; Faivre-Finn, C. ; Felip, E. ; Garrido, P. ; Girard, N. ; Guckenberger, M. ; Haanen, J. ; Le Pechoux, C. ; Mornex, F. ; Ozsahin, M. ; Paz-Ares, L. ; Planchard, D. ; Raben, D. ; Ramalingam, S. ; Reck, M. ; Smit, E. ; Stahel, R. ; Stenzinger, A. ; Swanton, C. ; Vallone, S. ; Garassino, M. C. / Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). In: Annals of Oncology. 2019 ; Vol. 30, No. 2. pp. 161-165.

@article{946be07398c64dc99112917e221bf666,

title = "Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)",

keywords = "PROGRAMMED DEATH LIGAND-1, CLINICAL BENEFIT, RADIOTHERAPY, EXPRESSION, MAGNITUDE, PD-L1",

author = "S. Peters and U. Dafni and M. Boyer and {De Ruysscher}, D. and C. Faivre-Finn and E. Felip and P. Garrido and N. Girard and M. Guckenberger and J. Haanen and {Le Pechoux}, C. and F. Mornex and M. Ozsahin and L. Paz-Ares and D. Planchard and D. Raben and S. Ramalingam and M. Reck and E. Smit and R. Stahel and A. Stenzinger and C. Swanton and S. Vallone and Garassino, {M. C.}",

year = "2019",

month = feb,

doi = "10.1093/annonc/mdy553",

language = "English",

volume = "30",

pages = "161--165",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "2",

}

Peters, S, Dafni, U, Boyer, M, De Ruysscher, D, Faivre-Finn, C, Felip, E, Garrido, P, Girard, N, Guckenberger, M, Haanen, J, Le Pechoux, C, Mornex, F, Ozsahin, M, Paz-Ares, L, Planchard, D, Raben, D, Ramalingam, S, Reck, M, Smit, E, Stahel, R, Stenzinger, A, Swanton, C, Vallone, S & Garassino, MC 2019, 'Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)', Annals of Oncology, vol. 30, no. 2, pp. 161-165. https://doi.org/10.1093/annonc/mdy553

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). / Peters, S.; Dafni, U.; Boyer, M.; De Ruysscher, D.; Faivre-Finn, C.; Felip, E.; Garrido, P.; Girard, N.; Guckenberger, M.; Haanen, J.; Le Pechoux, C.; Mornex, F.; Ozsahin, M.; Paz-Ares, L.; Planchard, D.; Raben, D.; Ramalingam, S.; Reck, M.; Smit, E.; Stahel, R.; Stenzinger, A.; Swanton, C.; Vallone, S.; Garassino, M. C.

In: Annals of Oncology, Vol. 30, No. 2, 02.2019, p. 161-165.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

AU - Peters, S.

AU - Dafni, U.

AU - Boyer, M.

AU - De Ruysscher, D.

AU - Faivre-Finn, C.

AU - Felip, E.

AU - Garrido, P.

AU - Girard, N.

AU - Guckenberger, M.

AU - Haanen, J.

AU - Le Pechoux, C.

AU - Mornex, F.

AU - Ozsahin, M.

AU - Paz-Ares, L.

AU - Planchard, D.

AU - Raben, D.

AU - Ramalingam, S.

AU - Reck, M.

AU - Smit, E.

AU - Stahel, R.

AU - Stenzinger, A.

AU - Swanton, C.

AU - Vallone, S.

AU - Garassino, M. C.

PY - 2019/2

Y1 - 2019/2

KW - PROGRAMMED DEATH LIGAND-1

KW - CLINICAL BENEFIT

KW - RADIOTHERAPY

KW - EXPRESSION

KW - MAGNITUDE

KW - PD-L1

U2 - 10.1093/annonc/mdy553

DO - 10.1093/annonc/mdy553

M3 - Editorial

VL - 30

SP - 161

EP - 165

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -